Pharmaceutical companies source raw materials, including active pharmaceutical ingredients (APIs) and key intermediates, through qualified suppliers who meet regulatory purity standards, documented manufacturing controls, and traceable supply chains, often spanning multiple countries. A growing share of buyers are now actively diversifying away from single-country sourcing, particularly heavy reliance on Chinese API manufacturing, due to geopolitical